Dysregulation of the ALDH1A3/PML-RARα axis promotes the progression of acute promyelocytic leukemia.

Saved in:
Bibliographic Details
Title: Dysregulation of the ALDH1A3/PML-RARα axis promotes the progression of acute promyelocytic leukemia.
Authors: Cai J; Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China; Department of Hematology, The General Hospital of Western Theater Command, Chengdu, 610083, China; International Joint Research Center for Precision Biotherapy, Ministry of Science and Technology, Chongqing, 400038, China., Liang CH; Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China; International Joint Research Center for Precision Biotherapy, Ministry of Science and Technology, Chongqing, 400038, China; Jin-feng Laboratory, Chongqing, 401329, China., Han LP; Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China; International Joint Research Center for Precision Biotherapy, Ministry of Science and Technology, Chongqing, 400038, China; Jin-feng Laboratory, Chongqing, 401329, China., Jiang HY; Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China; International Joint Research Center for Precision Biotherapy, Ministry of Science and Technology, Chongqing, 400038, China; Jin-feng Laboratory, Chongqing, 401329, China., Duan JJ; Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China; International Joint Research Center for Precision Biotherapy, Ministry of Science and Technology, Chongqing, 400038, China; Jin-feng Laboratory, Chongqing, 401329, China., Li F; Department of Hematology, The Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing, 400037, China., Liu J; Department of Hematology, The Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing, 400037, China., Liang C; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China., Gao L; Department of Hematology, The Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing, 400037, China. Electronic address: gaolei@tmmu.edu.cn., Yu SC; Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China; International Joint Research Center for Precision Biotherapy, Ministry of Science and Technology, Chongqing, 400038, China; Jin-feng Laboratory, Chongqing, 401329, China. Electronic address: yushicang@tmmu.edu.cn.
Source: Cancer letters [Cancer Lett] 2026 Apr 01; Vol. 642, pp. 218280. Date of Electronic Publication: 2026 Jan 22.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-7980
DOI:10.1016/j.canlet.2026.218280